tilatamig samrotecan

**Tilatamig samrotecan (AZD9592)** is a bispecific antibody-drug conjugate (ADC) developed by AstraZeneca targeting **EGFR** and **c-Met** on tumor cells to deliver a **topoisomerase I inhibitor (TOP1i)** payload, inducing double-strand DNA breaks and tumor cell death. It demonstrates broad preclinical efficacy across NSCLC patient-derived xenograft models, including EGFR mutant/wild-type, KRAS mutant/wild-type, and tumors resistant to prior EGFR TKIs (e.g., osimertinib), c-Met TKIs (e.g., savolitinib), chemotherapy, or ALK TKIs. Currently in **Phase 1** trials (e.g., EGRET, NCT05647122) for advanced solid tumors, including monotherapy and combinations (e.g., with osimertinib), with activity noted in colorectal, NSCLC, and other malignancies.[1][2][3][5][10]

Other names

tilatamig samrotecan